Jackson Creek Investment Advisors LLC Invests $463,000 in Catalyst Pharmaceuticals, Inc. $CPRX

Jackson Creek Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, HoldingsChannel reports. The fund purchased 19,824 shares of the biopharmaceutical company’s stock, valued at approximately $463,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CPRX. Deerfield Management Company L.P. grew its holdings in shares of Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 43.8% during the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after buying an additional 770,198 shares in the last quarter. Fundsmith LLP grew its holdings in shares of Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after buying an additional 654,721 shares in the last quarter. Glenmede Investment Management LP grew its holdings in shares of Catalyst Pharmaceuticals by 781.8% during the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after buying an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Catalyst Pharmaceuticals by 30.6% during the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after buying an additional 554,200 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Down 0.0%

CPRX opened at $31.32 on Thursday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The company has a 50 day moving average of $27.29 and a two-hundred day moving average of $24.92. The company has a market cap of $3.83 billion, a P/E ratio of 18.00, a P/E/G ratio of 0.91 and a beta of 0.72.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $32.17.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).